Videos

NYU Grossman School of Medicine’s Galen Hu, MD, and Andrea Blitzer, MD, sit down with Eduardo C. Alfonso, MD, of Bascom Palmer Eye Institute, to discuss how ophthalmologists are leveraging social media not just to promote practices, but to educate patients.

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring the importance of a thorough evaluation.

Attendees of the AAO 2025 annual meeting will have a chance to preview the virtual technician training platform on October 19, at 10:30 am in the Academy Theater, Hall WB1, Booth 2761.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient communication to build confidence and personalize treatment in evolving clinical settings.

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

From early experiences in India to fellowship training at Wills Eye Hospital, Dr. Ansari discusses how ophthalmologists can make a lasting impact worldwide.

A panelist discusses how a 76-year-old patient with neovascular age-related macular degeneration (nAMD) initially stable on bevacizumab developed recurrent subretinal fluid requiring a switch to aflibercept 2 mg, but after experiencing sterile inflammatory responses to both aflibercept 2 and 8 mg doses, was successfully treated with faricimab every 6 weeks, demonstrating the value of having structurally different anti-VEGF agents to minimize cross-antigenicity when immune responses occur.

A panelist discusses how a 62-year-old patient with age-related macular degeneration (AMD) who could never be extended beyond 4-week intervals with aflibercept 2 mg achieved complete macular drying and improved vision with aflibercept 8 mg, though temporary vision loss from acute IOP elevation required dose modification to 0.06 mL (6.86 mg) to maintain efficacy while avoiding pressure-related complications.

A panelist discusses how an 83-year-old patient with diabetic macular edema (DME) who showed suboptimal response to standard anti-VEGF therapies, including aflibercept 2 mg and faricimab, ultimately achieved significant visual and anatomic improvement when switched to high-dose aflibercept (8 mg), demonstrating the enhanced efficacy of the higher molar dose formulation.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Dr Miere presented the ACTOR study, illuminating vascular remodeling in patients with neovascular AMD, and the HERMES study, investigating perfusion changes in central retinal vein occlusion

María Berrocal, MD, spoke about the Vit-Buckle Society (VBS), which has become a regular feature at the European Society of Retina Specialists annual meeting

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Residents across ophthalmology, optometry, and retina care were recognized for leadership, research, and dedication to advancing patient care.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

An expert discusses evolving best practices in the diagnosis and management of Demodex blepharitis, highlighting collarettes as pathognomonic and sufficient for diagnosis, the importance of targeting high-risk patient groups for treatment, and the promise of a new pharmacologic therapy that shifts care toward a more effective, flexible, and patient-centered approach.